ObsEva SA's Yselty (linzagolix) is positioned, with data announced on 6 July, to be the third gonadotropin-releasing hormone (GnRH) receptor antagonist on the market in the US for the treatment of heavy menstrual bleeding in women with uterine fibroids, but it will be the Swiss biopharma's first commercial product if it successfully clears regulatory approval.
"If approved, linzagolix would be the first commercial product for ObsEva, turning us from a pure development organization to one...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
